Compare AGEN & EML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGEN | EML |
|---|---|---|
| Founded | 1994 | 1858 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 133.9M |
| IPO Year | 1999 | 1995 |
| Metric | AGEN | EML |
|---|---|---|
| Price | $3.23 | $21.70 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 672.7K | 15.1K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 1.98% |
| EPS Growth | 100.00 | ★ 185.40 |
| EPS | ★ 1.02 | 0.11 |
| Revenue | $42,877,086.00 | ★ $248,970,345.00 |
| Revenue This Year | $107.63 | $19.05 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $3.33 | $196.45 |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $2.71 | $17.61 |
| 52 Week High | $7.34 | $26.76 |
| Indicator | AGEN | EML |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 53.16 |
| Support Level | $2.93 | $21.54 |
| Resistance Level | $3.26 | $22.80 |
| Average True Range (ATR) | 0.22 | 0.49 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 36.93 | 78.53 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.